For decades, the humble aspirin tablet occupied a curious place in medicine: a cheap, ubiquitous painkiller that a growing body of research suggested might do far more than relieve a headache. Observational studies and early clinical trials hinted that people who took aspirin regularly developed cancer less often than those who did not, and the idea that a penny-per-day pill could double as a cancer-prevention drug became one of the most tantalizing hypotheses in preventive medicine. A new evidence review published in the Journal of General Internal Medicine now delivers a sobering verdict for one large group of patients. Harry B. Burke of the George Washington University School of Medicine and Stephanie G. Wheeler of the University of Washington, writing as part of the Society of General Internal Medicine’s Evidence-Based Medicine effort, conclude that for adults aged 65 and older, taking a low dose of aspirin every day does not lower the risk of developing cancer.

The conclusion matters because older adults are precisely the population in which any chemopreventive effect would be most valuable. Cancer incidence rises steeply with age, and the majority of cancer diagnoses in high-income countries occur in people over 65. If a safe, inexpensive, widely available medication could meaningfully blunt that risk, the public health implications would be enormous. The new summary, formatted as a Bottom Line Summary intended to distill evidence for practicing clinicians, cuts against that hope. Its patient-facing message is blunt: for those age 65 and older, taking a low dose aspirin every day does not lower cancer risk.

To understand why the field arrived at this point, it helps to trace the arc of the aspirin hypothesis. Aspirin, or acetylsalicylic acid, works by irreversibly inhibiting cyclooxygenase enzymes, thereby suppressing production of prostaglandins and thromboxane. That mechanism explains its classic effects on pain, fever, inflammation, and platelet aggregation, and it also supplied a plausible biological route to cancer prevention. Chronic inflammation is a recognized contributor to tumor development, and prostaglandin signaling has been implicated in processes ranging from cell proliferation to angiogenesis. Epidemiologists observed that people who took aspirin regularly appeared to have lower rates of colorectal cancer in particular, and randomized trials designed to test aspirin for cardiovascular prevention began to report, on longer follow-up, apparent reductions in cancer incidence and mortality among those assigned to the drug.

That evidence base, however, was never as clean as the headlines suggested. The randomized trials that generated the most optimistic findings were generally designed and powered to detect cardiovascular events, not cancer, and their cancer results emerged from post hoc analyses with varying durations of follow-up. Observational studies, for their part, are vulnerable to confounding: people who take aspirin regularly differ in many ways from people who do not, including in health-seeking behavior, access to care, and screening rates. When the evidence was assembled systematically, the signal weakened. A 2020 updated systematic review and subgroup meta-analysis of 29 randomized clinical trials of long-term aspirin use for primary cancer prevention, cited in the new summary, examined the totality of trial data and found that the hoped-for protective effect was not consistently supported across cancer types, populations, and doses.

Large randomized trials provided some of the most decisive tests. The ASCEND study, published in the New England Journal of Medicine in 2018, randomized more than 15,000 people with diabetes to aspirin or placebo and found that while aspirin reduced serious vascular events, it also increased major bleeding, and it did not produce the kind of broad benefit that would justify routine use. The JPAD trial in Japanese patients with type 2 diabetes and its ten-year observational follow-up, also published in 2018, examined aspirin’s effects in a diabetic population and found no evidence of a cancer chemopreventive benefit. These trials, conducted in populations at elevated vascular risk who might have been expected to benefit most, consistently failed to demonstrate that low-dose aspirin prevents cancer, while repeatedly confirming its capacity to cause bleeding.

The bleeding issue is central to any risk-benefit calculation. Aspirin’s inhibition of platelet function is permanent for the lifespan of each platelet, and because platelets circulate for roughly a week to ten days, even low doses produce a sustained anti-hemostatic effect. In younger and middle-aged adults this translates into a modest but real excess of gastrointestinal hemorrhage and, less commonly, hemorrhagic stroke. In older adults the risk is amplified: age-related changes in the gastric mucosa, higher prevalence of Helicobacter pylori infection and other comorbidities, greater use of interacting medications such as anticoagulants and nonsteroidal anti-inflammatory drugs, and increased frailty all raise the likelihood that bleeding will be serious rather than merely inconvenient. A prevention strategy that offers no cancer benefit while adding bleeding risk to a 75-year-old is, on its face, difficult to defend.

Professional bodies have been moving in this direction for several years. In the United States, the Preventive Services Task Force in recent guidance narrowed its recommendation on aspirin for primary cardiovascular prevention, declining to recommend initiation in adults 60 and older and suggesting that any decision to start aspirin in adults 40 to 59 at high cardiovascular risk should be individualized. The cancer-prevention rationale, once a secondary argument in favor of aspirin, has largely fallen away as trial evidence accumulated. The new Bottom Line Summary consolidates that shift for the specific question of cancer prevention in older adults, aligning clinical guidance with the randomized evidence rather than with the earlier observational enthusiasm.

The summary also illustrates the value of the evidence-based medicine approach it represents. Rather than relying on mechanistic plausibility or on the accumulated weight of observational associations, Burke and Wheeler, with the SGIM Evidence-Based Medicine Task Force, distilled the randomized trial evidence into a single actionable conclusion. The authors report no funding related to the submission and no conflicts of interest, and the work was reviewed through the SGIM EBM Subcommittee. In a field where enthusiasm for a cheap intervention can outpace the data, such structured syntheses serve as a corrective, translating complex and sometimes contradictory trial literature into guidance that a busy primary care clinician can apply directly in the examination room.

For patients, the practical takeaway is straightforward. People aged 65 and older should not start taking daily low-dose aspirin with the expectation of preventing cancer, and those who are taking it for that purpose have grounds to discuss stopping with their physician. Aspirin retains clear, well-established roles, including in the treatment of pain and fever and in the secondary prevention of cardiovascular events in people who have already had a heart attack or ischemic stroke, where its benefits demonstrably outweigh its risks. What the accumulating evidence has removed is the justification for aspirin as a general-purpose preventive pill in healthy older people. The once-promising idea that a daily tablet could ward off both heart attacks and cancer has, for the older population, been narrowed by the data: the cancer-prevention half of that promise has not survived rigorous testing, and the decision to take aspirin should rest on individualized assessment of cardiovascular benefit against bleeding risk, not on the hope of avoiding a cancer diagnosis.

Subject of Research: Low-dose aspirin for primary cancer prevention in older adults

Article Title: EBM BLS: Low Dose Aspirin Does Not Reduce the Risk of Cancer in Older Adults

Article References: Burke, H. B., & Wheeler, S. G. (2026). EBM BLS: Low Dose Aspirin Does Not Reduce the Risk of Cancer in Older Adults. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10876-8

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10876-8

Keywords: aspirin, cancer prevention, chemoprevention, older adults, geriatrics, primary prevention, evidence-based medicine, randomized trials, bleeding risk, Journal of General Internal Medicine, ASCEND trial, risk-benefit